In my December 2016 Life Science Leader outlook article sharing predictions for 2017, I argued it was going to be the year to watch biosimilars. Having arrived at the tail end of 2017, I stick by my original claim, though with a few exceptions. The U.S. and some European countries still have not seen significant biosimilar uptake or pricing competition. Major U.S. payers have been slow to offer up their prized primary formulary positions to biosimilars, while patients and physicians remain uncertain of or in the dark about biosimilars in general. But that doesn’t mean there hasn’t been any progress.